Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin LymphomaHemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmActive, not recruitingPhase 1 / Phase 22026-09-24NCT04981899

1 results · Page 1 of 1

Swipe the table sideways for more columns.

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Irkutsk Regional Cancer CenterIrkutskRussia1
National Medicine Research Center of oncology named after N.N. PetrovSaint PetersburgRussia1
St. Petersburg State Pavlov Medical UniversitySaint PetersburgRussia1